House of Lords Business
Show full summary

The Countess of Mar to ask Her Majesty's Government whether the action taken by the Medicines and Healthcare Products Regulatory Agency in 2012–13 to undertake enhanced pharmacovigilance alongside routine signal detection for the HPV vaccine was effective in preventing unfounded safety concerns; and if not, whether they will ask the Medicines and Healthcare Products Regulatory Agency to conduct further heightened pharmacovigilance at specific centres to assess those who suspect they have an adverse reaction to the HPV vaccination.  HL1965

Question HL1965: tabled on 12 October 2017 and due for answer by 26 October 2017

This type of business sits within the Questions & Statements category.

This question has been answered by the relevant Government Department.

Question text

The Countess of Mar to ask Her Majesty's Government whether the action taken by the Medicines and Healthcare Products Regulatory Agency in 2012–13 to undertake enhanced pharmacovigilance alongside routine signal detection for the HPV vaccine was effective in preventing unfounded safety concerns; and if not, whether they will ask the Medicines and Healthcare Products Regulatory Agency to conduct further heightened pharmacovigilance at specific centres to assess those who suspect they have an adverse reaction to the HPV vaccination.  HL1965
Legend for business item text
† Item that is new or altered.
* Item is an oral question.
Numbers starting HL are unique identifiers for written questions, Bills or papers.

Member's Registered Interests

There are no interests to show.

Main Member

The Countess of Mar
Crossbench
Excepted Hereditary